New combo therapy for cervical cancer shows promise in early trial

NCT ID NCT00957411

Completed Disease control Sponsor: Institut Curie Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested whether adding the targeted drug cetuximab to standard chemoradiation (cisplatin plus radiation) improves outcomes for people with locally advanced cervical cancer (stages IB2 to IIIB). 76 participants were randomly assigned to receive either chemoradiation alone or chemoradiation plus cetuximab. The study measured recurrence-free survival at 2 years and treatment side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cetuximab (a targeted antibody) and cisplatin (chemotherapy)
What this could lead to: If successful, this could show that adding cetuximab to standard chemoradiation improves recurrence-free survival for locally advanced cervical cancer.
What could go wrong: This is a small, early-phase trial (76 people) and results may not apply broadly. Adding cetuximab could increase side effects without clear benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CERVICAL CANCER

Contacts and locations

Locations

Institut Curie Hopital

Paris, 75248, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.